BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3445 related articles for article (PubMed ID: 19644872)

  • 1. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
    van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
    Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X; Jia R; Zhao J; Li Z
    J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies.
    Tamai M; Kawakami A; Uetani M; Takao S; Arima K; Iwamoto N; Fujikawa K; Aramaki T; Kawashiri SY; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
    Arthritis Rheum; 2009 Jun; 61(6):772-8. PubMed ID: 19479686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis.
    van der Woude D; Rantapää-Dahlqvist S; Ioan-Facsinay A; Onnekink C; Schwarte CM; Verpoort KN; Drijfhout JW; Huizinga TW; Toes RE; Pruijn GJ
    Ann Rheum Dis; 2010 Aug; 69(8):1554-61. PubMed ID: 20448290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Anti Cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis?
    Girelli F; Foschi FG; Bedeschi E; Calderoni V; Stefanini GF; Martinelli MG
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):127-30. PubMed ID: 15180353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
    Verpoort KN; Jol-van der Zijde CM; Papendrecht-van der Voort EA; Ioan-Facsinay A; Drijfhout JW; van Tol MJ; Breedveld FC; Huizinga TW; Toes RE
    Arthritis Rheum; 2006 Dec; 54(12):3799-808. PubMed ID: 17133560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early prediction of joint destruction in rheumatoid arthritis].
    Eguchi K
    Clin Calcium; 2007 Apr; 17(4):517-25. PubMed ID: 17404480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.
    Zeng X; Ai M; Tian X; Gan X; Shi Y; Song Q; Tang F
    J Rheumatol; 2003 Jul; 30(7):1451-5. PubMed ID: 12858440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
    Verpoort KN; van Gaalen FA; van der Helm-van Mil AH; Schreuder GM; Breedveld FC; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2005 Oct; 52(10):3058-62. PubMed ID: 16200610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 173.